Skip to content

Study · Randomized controlled trial · n = 61 · 2008

2 results

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial.

Lee TH, Lin YH, Seow KM, Hwang JL, Tzeng CR, Yang YS

Fertility and sterility11 Dec 2007Cited by 35 (Europe PMC)

PMID18054932 (opens in a new tab)DOI10.1016/j.fertnstert.2007.06.029 (opens in a new tab)PepBankPUB-18054932
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In stimulated patients, premature LH surge was significantly lower with cetrorelix: 19.4% (6/31) versus 43.4% (13/30) without cetrorelix.

    In plain wordsIn stimulated patients, premature LH surge was lower with cetrorelix: 19.4% versus 43.4% without cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    DecreasePremature LH surge
    Study

    n = 61

    Comparator
    Letrozole and gonadotropins without cetrorelix
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mgAs given in this study (human).

    Measurements

    Premature LH surge rate
    19.4%
    cetrorelix (group II, 6/31)
    Premature LH surge rate
    43.4%
    no cetrorelix (group I, 13/30)

    Source sentences

    Summary
    Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4% [13/30] vs. 19.4% [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 +/- 28.5 vs. 907.5 +/- 27.3 IU).
    4 context sentences
    Summary · context
    Prospective, randomized clinical trial.
    Summary · context
    Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups.
    Summary · context
    These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix.
    Summary · context
    Main outcome measure(s)Rate of premature LH surge.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In stimulated patients, gonadotropin use was significantly higher with cetrorelix: 907.5 +/- 27.3 versus 817.5 +/- 28.5 IU without cetrorelix.

    In plain wordsIn stimulated patients, gonadotropin use was higher with cetrorelix than without cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    IncreaseGonadotropin amount
    Study

    n = 61

    Comparator
    Letrozole and gonadotropins without cetrorelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mgAs given in this study (human).

    Measurements

    Gonadotropin amount, mean
    907.5 IU
    cetrorelix (group II); SD 27.3
    Gonadotropin amount, mean
    817.5 IU
    no cetrorelix (group I); SD 28.5

    Source sentences

    Summary
    Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4% [13/30] vs. 19.4% [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 +/- 28.5 vs. 907.5 +/- 27.3 IU).
    3 context sentences
    Summary · context
    Prospective, randomized clinical trial.
    Summary · context
    Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups.
    Summary · context
    These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.